Tags

Type your tag names separated by a space and hit enter

Epidemiology of dyslipidemia in chronic kidney disease.
Clin Exp Nephrol. 2014 Apr; 18(2):185-8.CE

Abstract

Dyslipidemia is an established risk factor for atherosclerotic disease, such as stroke and ischemic heart disease, and is often detected in patients with chronic kidney disease (CKD). The role of dyslipidemia in CKD progression, however, is not well understood. CKD patients are heterogeneous and may include those who are malnourished or have hypoalbuminemia associated with proteinuria and a low estimated glomerular filtration rate (eGFR). Recent intervention trials showed no clear-cut benefits of statin treatment, particularly for CKD patients on dialysis. In CKD patients, multiple confounding variables such as proteinuria and the presence of cardiovascular disease may mask the effects of statins. Among them, proteinuria is a potent predictor of CKD progression (eGFR decline) and the development of end-stage renal disease. CKD patients are at high risk not only for end-stage renal disease, but also for cardiovascular disease, infection, malnutrition, and other comorbid conditions frequently associated with the elderly population. Evaluation and the target range of treatment of dyslipidemia should be individualized.

Authors+Show Affiliations

Dialysis Unit, University Hospital of the Ryukyus, Nishihara, Japan, chihokun@med.u-ryukyu.ac.jp.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

24408220

Citation

Iseki, Kunitoshi. "Epidemiology of Dyslipidemia in Chronic Kidney Disease." Clinical and Experimental Nephrology, vol. 18, no. 2, 2014, pp. 185-8.
Iseki K. Epidemiology of dyslipidemia in chronic kidney disease. Clin Exp Nephrol. 2014;18(2):185-8.
Iseki, K. (2014). Epidemiology of dyslipidemia in chronic kidney disease. Clinical and Experimental Nephrology, 18(2), 185-8. https://doi.org/10.1007/s10157-013-0891-8
Iseki K. Epidemiology of Dyslipidemia in Chronic Kidney Disease. Clin Exp Nephrol. 2014;18(2):185-8. PubMed PMID: 24408220.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Epidemiology of dyslipidemia in chronic kidney disease. A1 - Iseki,Kunitoshi, Y1 - 2014/01/11/ PY - 2013/09/17/received PY - 2013/10/07/accepted PY - 2014/1/11/entrez PY - 2014/1/11/pubmed PY - 2014/12/30/medline SP - 185 EP - 8 JF - Clinical and experimental nephrology JO - Clin Exp Nephrol VL - 18 IS - 2 N2 - Dyslipidemia is an established risk factor for atherosclerotic disease, such as stroke and ischemic heart disease, and is often detected in patients with chronic kidney disease (CKD). The role of dyslipidemia in CKD progression, however, is not well understood. CKD patients are heterogeneous and may include those who are malnourished or have hypoalbuminemia associated with proteinuria and a low estimated glomerular filtration rate (eGFR). Recent intervention trials showed no clear-cut benefits of statin treatment, particularly for CKD patients on dialysis. In CKD patients, multiple confounding variables such as proteinuria and the presence of cardiovascular disease may mask the effects of statins. Among them, proteinuria is a potent predictor of CKD progression (eGFR decline) and the development of end-stage renal disease. CKD patients are at high risk not only for end-stage renal disease, but also for cardiovascular disease, infection, malnutrition, and other comorbid conditions frequently associated with the elderly population. Evaluation and the target range of treatment of dyslipidemia should be individualized. SN - 1437-7799 UR - https://www.unboundmedicine.com/medline/citation/24408220/Epidemiology_of_dyslipidemia_in_chronic_kidney_disease_ L2 - https://dx.doi.org/10.1007/s10157-013-0891-8 DB - PRIME DP - Unbound Medicine ER -